Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $2.42M rose 273.6% year over year, ahead of the +6.4% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +97.6% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +273.6% holds above the trailing-twelve-month pace of +6.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 239K USD
- Year-over-year change
- -70.1%
- 3-year CAGR
- +97.6%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 239K | -70.1% |
| FY2024 | 2024-12-31 | 798K | +2.8% |
| FY2023 | 2023-12-31 | 776K | +2403.2% |
| FY2022 | 2022-12-31 | 31K | — |
Accounts Payables vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 accounts payables of $2.01M is the 5th largest of the 11 companies compared; the peer median is $35.5K.
- Its year-over-year change of +6.4% is the 8th highest of 11, against a peer median of +55.0%.
- Over three fiscal years its annual growth of +97.6% compares with a peer median of -33.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ZURAZura Bio Limited | LTM Mar 2026 | $4.96M | -177.6% | — | — |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $3.31M | +280.1% | +21.9% | — |
| LTM Mar 2026 | $2.51M | +12.5% | — | 1116.0% | |
| LTM Mar 2026 | $2.14M | +288.2% | — | 15.5% | |
| LTM Mar 2026 | $2.01M | +6.4% | +97.6% | — | |
| LTM Mar 2026 | $793K | -49.2% | -33.2% | 2.8% | |
| LTM Mar 2026 | $399K | +1230.0% | -34.4% | 0.6% | |
| LTM Mar 2026 | $370K | -77.8% | — | 3.3% | |
| LTM Mar 2026 | $325K | +38.3% | -33.1% | 550.8% | |
| LTM Mar 2026 | $262K | +132.6% | -50.3% | — | |
| LTM Mar 2026 | $254K | +71.6% | — | 0.4% | |
| Peer median (excluding AARD) | $35.5K | +55.0% | -33.2% | 3.3% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Depreciation & Amortization | 110K | 97K | 16K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 412K | 313K | 439K | 3.95M |
| Change in Working Capital | (1.31M) | (81K) | 1.57M | 356K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 31K | 776K | 798K | 239K |
| Other Working Capital | (1.34M) | (857K) | 775K | 117K |
| Other Non-Cash Items | 3.81M | 1.06M | 473K | 421K |
| Operating Cash Flow | (10.54M) | (5.82M) | (18.09M) | (54.17M) |
| Capital Expenditures | 0 | 0 | (109K) | (95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (11.89M) | (129.6M) |
| Sales of Investments | 0 | 0 | 0 | 80.03M |
| Other Investing Activities | (1M) | 0 | 0 | 0 |
| Investing Cash Flow | (1M) | 0 | (12M) | (49.67M) |
| Debt Repayment | (1M) | 0 | 0 | 0 |
| Common Stock Issued | 225K | 0 | 332K | 89.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1M | 0 | (3.34M) | 0 |
| Financing Cash Flow | 225K | 0 | 81.99M | 89.25M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.32M) | (5.82M) | 51.91M | (14.59M) |
| Free Cash Flow | (10.54M) | (5.82M) | (18.2M) | (54.27M) |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.